Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

NCT05038592 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT05038592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05038592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 4, 2022
Completion date
January 29, 2027
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, chronic myelomonocytic leukemia-1, chronic myelomonocytic leukemia-2, myelodysplastic/myeloproliferative neoplasm